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Abstract
Purpose Transforming growth factor β1 (TGF-β1) plays a
role in cell proliferation and differentiation, and it can mod-
ulate immune response. In this work, we asked whether
levels of either TGF-β1 or mRNA of the corresponding
gene in plasma or tissue can be useful in diagnosing and/
or monitoring of the clinical course of inflammatory bowel
diseases (IBD).
Methods The study group consisted of 104 pediatric patients
with IBD: 36 with Crohn’s disease (CD) and 68 with ulcera-
tive colitis (UC); 42 children represented the control group.
TGF-β1 levels in plasma and intestinal mucosa were estimat-
ed by ELISA and immunohistochemistry (IHC), respectively.
Levels of TGF-β1 mRNA were determined by reverse tran-
scription and real-time PCR.
Results In patients with IBD, and in subgroups with CD and
UC, no significant differences in the TGF-β1 level in plas-
ma and tissue were found relative to the control group.
These variables were not dependent on the stage of the
disease, its activity or severity of endoscopic and histopath-
ological findings. TGF-β1 mRNA levels were significantly
higher in tissue samples withdrawn during the relapse of the
disease than in those taken during the remission or in the
control group. However, no correlation between TGF-β1
plasma levels and TGF-β1 mRNA amount in the intestinal
mucosa was observed.
Conclusions The TGF-β1 mRNA level, but not the amount
of the gene product, was significantly increased in the
pathologically changed tissue during the relapse of IBD.
We suggest that this parameter might be considered as a
potential prognostic value when assessing IBD in children.
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Introduction
Transforming growth factor β (TGF-β), especially its iso-
form 1, is known to be one of the major factors involved in
immunological homeostasis. Biological activity of TGF-β
consists of effects on cell proliferation and maturation or
immunomodulation [1–3]. Within particular organs and tis-
sues, TGF-β is involved in regenerative processes and upon
some conditions may be responsible for pathological fibro-
sis [4–6]. Long-term immunoregulatory disturbances are
proved to play a crucial role in the pathogenesis of numer-
ous diseases [4–9], thus TGF-β appears to be of great
interest in contemporary studies. Either insufficiency or
hyperactivity of TGF-β may be responsible for some dis-
eases, particularly due to its influence on immune response
and regenerative processes. Some clinical and experimental
studies indicated the role of TGF-β in chronic inflammatory
diseases, especially those of the bowels [10–14].
In the course of chronic inflammatory bowel diseases, the
cicatricial changes within the bowel appear to be related to the
activity of TGF-β, which is responsible for the fibrogenesis.
However it still remains unknownwhether an increased amount
of TGF-β in the inflamed tissue is the cause or only an innocent
response for the insult and damage of the tissue related to the
disease. Damage of the tissue is known to be one of the major
factors responsible for the activation of the TGF-β1 gene and
increased production of this cytokine in site [15, 16]. One may
also assume that chronic inflammation is determined by the
deficiency of TGF-β biological activity. It was reported that
mice lacking TGF-β activity presented with multi-organ in-
flammatory and necrotic changes shortly after birth [12, 17].
Within the immune system, TGF-β1 plays an immuno-
suppressive role preventing autoimmune and chronic inflam-
matory diseases. It inhibits the processes of activation of auto-
reactive lymphocytes T, production of auto-antibodies, and
thus, the self-antigens damage [18, 19]. The wide range of
data indicates the main role of altered function of cytokines,
including TGF-β1, in the pathogenesis of chronic inflamma-
tory diseases, thus, further studies, especially in children,
appear to be warranted [20, 21]. The aim of the study was to
evaluate the role of TGF-β1 in the pathogenesis of inflamma-
tory bowel diseases (IBD) and to assess whether levels of
either TGF-β1 and/or mRNA of its gene, in either plasma or
tissue expression, can be useful in diagnosing and/or moni-
toring of the clinical course of these diseases.
Methods
Patients
The study group consisted of 104 patients with IBD, includ-
ing 36 with Crohn’s disease (CD) and 68 with ulcerative
colitis (UC), at the age 1.5–18.4 years (mean, 13.0±4.5;
median, 14.5). Forty-two children represented the control
group, which consisted of 20 girls and 22 boys at the age
2.0–18.0 years (mean, 11.0±5.0; median, 11.0), who under-
went endoscopy because of the events of the gastrointestinal
(GI) bleedings (this relatively high number of pediatric
patients with GI bleedings resulted from the fact that the
Department of Pediatrics, Pediatric Gastroenterology, Hepa-
tology and Nutrition of the Medical University of Gdańsk
serves as one of pediatric gastroenterology reference centers
for Northern Poland, covering relatively large population); in
this group of patients, inflammatory processes, immune dis-
orders, malignancies, and nutritional abnormalities were ex-
cluded. None of the patients received immuno-modulating
drugs at least 6 months prior to the study. Most IBD patients
were treated with anti-inflammatory drugs (e.g., 5-amino sal-
icylic acid). Only minority, with more severe disease course or
during the relapse, used immunosuppresants (e.g., steroids or
azathioprine). However, since we have detailed data on drug
therapies only for a part of patients, this parameter was not
analyzed in this study.
Clinical parameters and samples’ collection
Endoscopic and histological classifications of intestinal mu-
cosa were performed according to the Porto criteria [22].
Among IBD patients, severities of CD and UC were esti-
mated according to the Hyams scale (Pediatric Crohn’s
Disease Activity Index) and the Truelove–Witts scale, re-
spectively [23, 24].
In patients in the acute phase of the IBD, both blood and
bowel tissue samples were obtainedwhile in those in remission,
the level of TGF-β in the serumwas assessed. In a few patients,
when the control endoscopy was mandatory, the level of TGF-
β was measured also in the bowel tissue. All samples were
obtained while performing obligatory diagnostic procedures.
Inflammatory parameters
The following inflammatory parameters were determined
for all subjects: C-reactive protein level (CRP), erythrocytes
sedimentation rate, and full blood count.
Determination of TGF-β1 level
The TGF-β1 level in plasma was estimated by ELISA
(Quantikine TGF-β1 R&D Systems, USA), according to
manufacturer’s instructions. Amount of the TGF-β1 protein
in the intestinal mucosa was estimated by immunohisto-
chemistry (IHC; Vectastain ABC Kit, Vector Laboratories,
USA) and microscopic observations at the final magnifica-
tions of ×200 and ×400. The results were described in a
semi-quantitative scale (0, 1+, 2+, and 3+).
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Measurement of mRNA levels
The mRNA level in the intestinal tissue was determined by
reverse transcription and Real-Time PCR. Total RNA was
isolated by employing the Total RNA Prep Plus kit (A&A
Biotechnology, Poland), according to manufacturer’s
instructions. Concentration and quality of RNA samples
were determined spectrophotometrically (Smart Spec 3000
apparatus, Bio-Rad, USA). One microgram of RNA,
0.25 μg of oligo T18, and M-MLV enzyme (Promega, Mad-
ison, WI, USA) were used for reverse transcription in total
volume of 10 μl. The qPCR reaction contained 0.4 μl
cDNA, 180 nM each primer and iQSybrGreen Supermix
kit (Bio-Rad) and was performed in iCycler iQ (Bio-Rad) in
total volume of 20 μl. Primers for TGF-β1 and ACTB were
designed de novo using Primer3Plus based on BLAST,
ENSMBL, and AceView databases; TGF-β1: 5′-CAG
CAA CAA TTC CTG GCG ATA CC and TGFβ-2, 5′-
CGA AAG CCC TCA ATT TCC CCT C, bact1-1, 5′-TGT
GCC CAT CTA CGA GGG GTA TGC, and bact1-2, 5′-
GGTACATGG TGG TGC CGC CAG ACA. The reactions
were run in triplicates and the obtained data were averaged
followed by data analysis calculated with iQ ver. 3.1 soft-
ware (Bio-Rad). The ACTB gene was used as a control to
normalize the values in commonΔΔCt quantification meth-
od [25, 26].
Statistical analysis
Statistical analysis of the results was performed using non-
parametric tests: the Mann–Whitney test for comparison of
two groups, the ANOVA Kruskal–Wallis test for compari-
son of several groups, and the Spearman correlation test. For
qualitative parameters, the Pearson’s χ2 test was used, with
Yates correction if n<10. The results were considered sta-
tistically significant when p<0.05. The calculations were
performed employing Statistica 7 software (StatSoft Inc.,
OK, USA).
Ethical considerations
This study was approved by the Independent Bio-Ethical
Committee for Research at the Medical University of
Gdańsk (NKEBN/13/2004). Informed consent forms of
patients and controls (or their parents) were obtained.
Results
TGF-β1 plasma level
In the studied group of patients, the TGF-β1 plasma levels
were in the range of 0.11–55.10 ng/ml (mean, 7.01±
9.37 ng/ml; median, 3.51 ng/ml) (Table 1). No statistically
significant differences between the TGF-β1 plasma levels in
IBD patients and control group were noted, although p value
was 0.06. No statistically significant differences were also
observed between the UC and the CD patients and the
control group (p00.16) (Table 1).
No statistically significant differences were noted among
the TGF-β1 plasma levels in the particular phases of the
disease (mean TGF-β1 plasma levels were as follows: at the
time of diagnosis, 8.59 ng/ml; at the relapse, 7.22 ng/ml; and
at the remission, 7.91 ng/ml), and in the control group
(6.3 ng/ml; p00.22), as well as in the particular sub-
groups, the UC (p00.55) and the CD (p00.65) patients.
Moreover, no statistically significant differences were found
between TGF-β1 plasma levels at particular activity grades
of IBD relative to the control group (p00.27). The same was
true when UC and CD were considered separately, relative
to the control (p00.13 and 0.23, respectively).
In the studied group of children with IBD, the TGF-β1
plasma levels showed no correlation with endoscopic (p0
0.42) and histopathological (p00.55) activity of the disease.
Furthermore, no statistically significant correlations of TGF-
β1 plasma levels with CRP, SR, WBC, and platelet count
were noted (data not shown).
TGF-β1 levels in the intestinal tissue
The IHC studies were performed in intestinal tissue samples
in 72 children (IBD, 53; UC, 37; CD, 16; and the control
group, 19). The intensities of the IHC reaction specific to
TGF-β1 were assessed in the semi-quantitative scale as
follows: 1+ in 15 (19.2 %) children, 2+ in 39 (50 %), and
3+ in 24 patients (30.8 %). No statistically significant differ-
ences were noted between the intensity of IHC in the IBD
patients and in the control group and in the particular groups
of CD and UC patients (data not shown).
In the studied group of children, the intensity of IHC
showed no correlation with the disease activity neither in the
Table 1 Plasma concentration of TGF-β in the study groups and
subgroups
Group Number TGF-β1 concentration (ng/ml)a
Mean Median Min Max SD
Control 42 6.96 2.79 0.54 55.10 11.61
IBD 104 7.71 3.72 0.20 43.14 9.05
UC 68 7.86 3.54 0.20 43.14 9.83
CD 36 7.46 4.43 0.72 30.45 7.49
Statistical analysis: control vs. IBD (p00.06); CD vs. UC (p00.16)
a Results from three independent measurements in each sample (in-
cluding RNA extraction) are presented
SD standard deviation
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whole IBD group nor in the particular groups of CD and UC
patients (data not shown).
mRNA levels of the TGF-β1 gene
The mRNA levels of the TGF-β1 gene in the intestinal tissue
in the studied group of children are presented in Table 2. The
levels in the inflamed intestinal tissue were significantly
higher in IBD patients than in the control group (p00.002).
However, the mRNA levels in the tissue samples obtained
frommacroscopically unchanged intestinal regions in the IBD
patients in the active phase of the disease showed no signifi-
cant differences relative to the control group (p00.12).
Like in the whole IBD group, in the UC patients the
mRNA levels in the macroscopically changed intestinal
tissue were statistically higher than in the control group
(p00.02), and at the edge of statistical significance in the
CD patients in comparison with the control group (p00.05).
No statistically significant differences were noted between the
mRNA levels in the groups of CD and UC patients (p01.00).
Furthermore, the mRNA levels of the TGF-β1 gene in tissue
samples obtained from patients in the active phase of the
disease, but from the macroscopically unchanged intestinal
regions, showed no statistically significant differences with
the control group and in both CD and UC groups (p00.26).
Moreover, we have analyzed samples from 41 IBD
patients (28 UC patients and 13 CD patients) in which
samples of the intestinal tissue were withdrawn during colo-
noscopy at the active phase of the disease from both
changed and unchanged areas (Fig. 1). Statistically signifi-
cant differences were found between TGF-β1 mRNA levels
in changed and unchanged tissues when the whole group of
IBD was analyzed (p<0.001) as well as in the CD and UC
subgroups (p<0.001 in both cases), namely, the levels in the
changed tissue samples were higher than in unchanged
tissue samples (Fig. 1).
The comparison of TGF-β1 mRNA levels in particular
phases of the disease (Fig. 2) showed significantly higher
values in the relapse of the disease relative to both remission
(p00.01) and the control group (p00.04). However, no
statistically significant differences were noted between the
mRNA levels in the remission and the control group (p0
0.99), and between the mRNA levels in samples withdrawn
at the time of diagnosis and (1) the time of remission (p0
0.99), (2) the relapse (p00.12), and (3) the control group
(p00.80).
No statistically significant differences were noted in the
whole IBD group, and in both CD and UC subgroups, when
the mRNA levels in macroscopically changed intestinal
tissues at the active phase of the disease were tested in
relation to the endoscopic (IBD, p00.42; CD, p00.40; and
UC, p00.32) and histopathological (IBD, p00.55; CD, p0
0.95; and UC, p00.23) changes.
Interestingly, no statistically significant correlation was
observed between the TGF-β1 plasma levels and the TGF-
β1 mRNA levels in the macroscopically changed intestinal
tissue in the group of IBD patients (Rs00.19; p00.07) and in
both CD and UC subgroups (for CD, Rs00.07; p00.71 and
for UC, Rs00.24; p00.08).
Discussion
The wide range of cytokines plays a significant role in the
pathogenesis of the chronic inflammatory bowel diseases,
thus, intensive research estimating their levels either in the
blood or in the inflamed tissues employing immunohisto-
chemical and molecular methods, is being conducted [20,
27–31]. Furthermore, signaling pathways of particular cyto-
kines are being assessed at the molecular level [32, 33].
Most of the data are related to the blood levels of particular
cytokines due to the less invasive procedures of obtaining
blood samples comparing to obtaining tissue samples and
availability of numerous ELISA kits suitable for estimation
of cytokine levels in the blood [20, 28, 31, 33].
Table 2 TGF-β1 mRNA levels in intestinal tissue of the control group and the study groups
Sample Number TGF-β1 mRNA level (arbitrary units)a
Mean Median Min. Max SD
Control 42 0.08596 0.04028 0.00103 0.82469 0.16012
IBD-affected area 90 0.15040 0.06569 0.00068 1.59320 0.21443
UC 57 0.15512 0.07289 0.00068 0.85378 0.18372
CD 33 0.15782 0.06569 0.00296 1.59320 0.27999
IBD-unaffected area
(active stage of disease)
41 0.03852 0.02244 0.00108 0.30119 0.06087
a Results from three independent measurements in each sample (including RNA extraction) are presented. Statistical analysis: control vs. IBD
(affected area; p00.002); control vs. IBD (unaffected area; p00.12); control vs. UC (affected area; p00.02); control vs. CD (affected area; p00.05);
UC vs. CD (affected area; p01.0)
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Data referring the role of TGF-β1 in the pathogenesis of
the chronic inflammatory bowel disease, especially in chil-
dren, are rather scarce [20, 21]. In the group of children
described in this report and suffering from chronic inflam-
matory bowel diseases, the TGF-β1 plasma levels showed
no significant differences in both CD and UC patients and
the control group. Medical reports on this topic are equivo-
cal. Sturm et al. [34] presented no statistically significant
differences between the TGF-β1 and HGF (hepatocyte
growth factor) plasma levels in patients with IBD and the
control group. However, in other study, similarly to our
results, the tendency to the higher TGF-β1 plasma levels
in the IBD patients was noted [34]. No statistically signifi-
cant differences between the TGF-β1 plasma levels in
patients with CD and children with UC, were also noted in
the research by Kader et al. [20]. In that study, plasma levels
of over 70 cytokines and growth factors were estimated in
the group of 88 children with IBD (65 with UC and 23 with
CD). In patients with CD, plasma levels of four cytokines,
PLGF (placenta growth factor), IL-7, Il-12p40, and TGF-β1
were significantly higher in the remission than in the active
phase of the disease. However, in patients with UC, such
differences were proved to be related only to one cytokine,
IL-12p40 [20]. Those authors put stress on the distinct
profile of the cytokines’ activity in patients with CD and
patients with UC, which may be mainly explained by Th1
cell involvement in the immune response in CD patients,
and Th2 in UC patients. Furthermore, no decrease in the
cytokines’ plasma levels in the course of the clinical im-
provement was noted [20].
In the group of patients studied in this work, the TGF-β1























































Fig. 1 TGF-β1 mRNA level in
samples from the affected and
unaffected areas during active
stage of disease in the IBD
group (collective data). a
Values for the whole group and
b results for individual patients.
Results from three independent
measurements in each sample
(including RNA extraction) are
presented. In (a), the difference
between values presented for
































Fig. 2 TGF-β1 mRNA level at different stages of the disease in IBD
patients and in the control group. Results from three independent
measurements in each sample (including RNA extraction) are pre-
sented. Statistically significant differences are marked by asterisks
(the p values were 0.01 and 0.04 for comparison between relapse vs.
remission and remission vs. control, respectively)
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of the disease. It might be partly explained by rather low
severity of the disease at the time of diagnosis in the studied
group of children. Sturm et al. [34] presented no significant
differences between TGF-β1 plasma levels in 74 patients
with IBD (28 with UC, 45 with CD) in relation to particular
phases of the disease and to the control group. Our data
showed also no significant correlation between the TGF-β1
plasma levels and the results of the laboratory blood tests.
Besides the TGF-β1 plasma levels, the intestinal tissue
levels of TGF-β1 were estimated by IHC. No statistically
significant differences were noted between the intensity of
IHC in the IBD patients and in the control group, and in
particular subgroups of CD and UC patients. Previously,
Lawrence et al. [35] observed the diverse pattern of the IHC
intensity in relation to the type of IBD: in the patients with
CD, the intramural IHC was the most intense, while in the
patients with UC the highest signals were detected in submu-
cosal and within the lamina propria. The intensity of the IHC
correlated with the inflammatory infiltration in all patients and
it finally appeared to be the main factor affecting the IHC [35].
Numerous authors suggested a role for some other TGF-β
isoforms in the pathogenesis of IBD. Kazanawa et al. [36]
showed no intestinal tissue expression of the TGF-β1 gene in
adults with CD and UC. However in some of them, TGF-β2
and TGF-β3 isoforms were detected along with the intestinal
tissue production of FGF (fibroblast growth factor) and VEGF
(vascular endothelial growth factor) [36]. Noteworthy,
McKaig et al. [37] reported a similar expression of the TGF-
β1 gene in cell cultures of myofibroblasts obtained from
macroscopically unchanged or inflamed intestinal regions, in
both CD and UC patients. Furthermore, the presence of other
TGF isoforms was detected in cell cultures of myofibroblasts
obtained from inflamed intestinal regions: TGF- β2 mainly in
CD patients and TGF-β3 in UC patients [37]. In intestinal
myofibroblast cultures from CD patients, intense cell prolif-
eration, along with increased tissue inhibitors of metallopro-
teinases production was observed, what appeared to be
responsible for the predisposition to fibrosis and intestinal
strictures in this group of patients [38].
Our data showed that the mRNA levels in the intestinal
tissue were significantly higher in the IBD patients in the
active phase of the disease than in the control group. These
differences were prominent when tissue samples were
obtained from the macroscopically changed regions. The
tissue samples obtained from the patients in the active phase
of the disease, but from the macroscopically unchanged
intestinal regions, showed no statistically significant differ-
ences relative to the control group. This was also true for both
CD and UC subgroups. Del Zotto et al. [39] showed similar
relationships estimating the TGF-β1 levels in cell cultures.
Contrary to the CD patients, monocytes and lymphocytes T,
obtained from the lamina propria of UC patients, produced
more TGF-β1 than control cells [39].
It is intriguing that despite the above mentioned differ-
ences in the levels of TGF-β1 mRNA, no such differences
were detected in levels of the gene product (the TGF-β1
protein) in both plasma and tissue samples. The lack of
correlation between the tissue mRNA and the plasma pro-
tein levels might be explained by possible specificity of the
effects for TGF-β1 expression, restricted solely to the path-
ologically changed tissue. Such a hypothesis may be cor-
roborated by the fact that TGF-β1 mRNA levels in the
inflamed intestinal tissue were significantly higher in IBD
patients than in the control group, while analogous values
measured in tissue samples obtained from macroscopically
unchanged intestinal regions of the same patients showed no
significant differences relative to the control group. A lack
of the difference in the levels of the TGF-β1 protein be-
tween IBD patients and the control group, in the light of
significantly different corresponding mRNA levels, could
arise from the use of a semi-quantitative method for deter-
mination of the protein level. Alternatively, such a discrep-
ancy might result from a putative, extensive post-
transcriptional regulation of the TGF-β1 gene expression.
Our results indicated that TGF-β1 mRNA levels in the
intestinal tissue were significantly higher in tissue samples
obtained at the time of relapse than in tissue samples
obtained at the time of diagnosis. This may be due to the
signaling pathways disturbances and defects of regulatory
mechanisms essential in the active phase of the disease [40].
Since serial probing in different activity stages of the disease
is not recommended if there is no therapeutic consequences,
our results cannot be applied directly in estimating the
progress of the disease. However, one can speculate that if
tissue samples were withdrawn during medical procedures
anyway, then estimation of TGF-β1 mRNA levels might be
considered as a potential prognostic value of the course of
the disease, indicating unfavorable prognosis in the case of
increased levels.
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